Overview
- The executive order, signed Saturday, directs the FDA to speed reviews of qualifying psychedelics and asks HHS to match $50 million in state research funding.
- Trump publicly thanked Joe Rogan for elevating ibogaine and invited him to the Oval Office signing, and Rogan says a brief text exchange with the president helped prompt the action.
- The directive sets targets such as 60 days for DEA rescheduling after FDA approval and a three‑month FDA response window on some filings, which experts say would shave only a few months off current timelines.
- Ibogaine is a centerpiece of the discussion for its reported benefits in PTSD and addiction but it can trigger fatal heart rhythm problems, and U.S. researchers halted work on it in the 1990s with only small studies continuing abroad.
- Political scrutiny followed, with Rep. Jake Auchincloss warning the move looked like an attempt to appease Rogan over Iran policy rather than a decision grounded solely in safety and efficacy.